OBJECTIVES: We examined trends in HCV incident infection among injection drug users (IDUs) attending needle and syringe programs (NSPs) in Australia in 1995 to 2010. METHODS: We created a passive retrospective cohort of 724 IDUs who tested negative for HCV antibodies by a simple deterministic method linking partial identifiers to find repeat respondents in annual cross-sectional serosurveillance. RESULTS: We identified 180 HCV seroconversions over the study period, for a pooled incidence density of 17.0 per 100 person-years (95% confidence interval [CI] = 14.68, 19.66). Incidence density declined, from a high of 30.8 per 100 person-years (95% CI = 21.3, 44.6) in 2003 to a low of 4.0 (95% CI = 1.3, 12.3) in 2009. CONCLUSIONS: A decline in HCV incidence among Australian IDUs attending NSPs coincided with considerable expansion of harm reduction programs and a likely reduction in the number of IDUs, associated with significant changes in drug markets. Our results demonstrate the capacity of repeat cross-sectional serosurveillance to monitor trends in HCV incidence and provide a platform from which to assess the impact of prevention and treatment interventions.
OBJECTIVES: We examined trends in HCV incident infection among injection drug users (IDUs) attending needle and syringe programs (NSPs) in Australia in 1995 to 2010. METHODS: We created a passive retrospective cohort of 724 IDUs who tested negative for HCV antibodies by a simple deterministic method linking partial identifiers to find repeat respondents in annual cross-sectional serosurveillance. RESULTS: We identified 180 HCV seroconversions over the study period, for a pooled incidence density of 17.0 per 100 person-years (95% confidence interval [CI] = 14.68, 19.66). Incidence density declined, from a high of 30.8 per 100 person-years (95% CI = 21.3, 44.6) in 2003 to a low of 4.0 (95% CI = 1.3, 12.3) in 2009. CONCLUSIONS: A decline in HCV incidence among Australian IDUs attending NSPs coincided with considerable expansion of harm reduction programs and a likely reduction in the number of IDUs, associated with significant changes in drug markets. Our results demonstrate the capacity of repeat cross-sectional serosurveillance to monitor trends in HCV incidence and provide a platform from which to assess the impact of prevention and treatment interventions.
Authors: M MacDonald; A D Wodak; R Ali; N Crofts; P H Cunningham; K A Dolan; M Kelaher; W M Loxley; I van Beek; J M Kaldor Journal: Med J Aust Date: 1997-03-03 Impact factor: 7.738
Authors: Liviana Calzavara; Ann N Burchell; Carol Major; Robert S Remis; Paul Corey; Ted Myers; Peggy Millson; Evelyn Wallace Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: A Esmaeili; A Mirzazadeh; G M Carter; A Esmaeili; B Hajarizadeh; H S Sacks; K A Page Journal: J Viral Hepat Date: 2016-10-28 Impact factor: 3.728
Authors: Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman Journal: Drug Alcohol Depend Date: 2015-04-13 Impact factor: 4.492
Authors: Louise Geddes; Jenny Iversen; Handan Wand; Aryan Esmaeili; Judith Tsui; Margaret Hellard; Gregory Dore; Jason Grebely; Paul Dietze; Julie Bruneau; Maria Prins; Megan D Morris; Naglaa H Shoukry; Andrew R Lloyd; Arthur Y Kim; Georg Lauer; Andrea L Cox; Kimberly Page; Lisa Maher Journal: Clin Infect Dis Date: 2020-01-01 Impact factor: 9.079
Authors: Chaturaka Rodrigo; Auda A Eltahla; Rowena A Bull; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Chris Estes; Homie Razavi; Andrew R Lloyd; Fabio Luciani Journal: J Infect Dis Date: 2016-08-28 Impact factor: 5.226
Authors: Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth Journal: Lancet Infect Dis Date: 2019-09-17 Impact factor: 25.071
Authors: Ashly E Jordan; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; David C Perlman; Denis Nash Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Fiona L Shand; Carolyn Day; William Rawlinson; Louisa Degenhardt; Nicholas G Martin; Elliot C Nelson Journal: Aust N Z J Public Health Date: 2014-04 Impact factor: 2.939
Authors: Aryan Esmaeili; Ali Mirzazadeh; Meghan D Morris; Behzad Hajarizadeh; Henry S Sacks; Lisa Maher; Jason Grebely; Arthur Y Kim; Georg Lauer; Andrea L Cox; Margaret Hellard; Paul Dietze; Julie Bruneau; Naglaa H Shoukry; Gregory J Dore; Andrew R Lloyd; Maria Prins; Kimberly Page Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079